Welcome to the OMA Blog

Weight loss medications have undergone a sea change in the past several years. With the rise of incretin therapies, two names have emerged as leaders: tirzepatide and semaglutide. They share many similarities. The frequency with which we hear these two drug names bandied about, along with their brand names — Mounjaro/Zepbound and Ozempic/Wegovy, respectively — can lead to confusion.

Learn how a low carb diet supports obesity treatment. Explore carbohydrate definitions, sex-specific metabolic effects, and clinical risks.

Learn about metabolic flexibility and its role in obesity treatment in this in-depth guide for healthcare providers.

Obesity is no longer a looming public health threat—it is a full-scale epidemic. More than 40% of U.S. adults live with obesity,1 driving increased risk of type 2 diabetes, cardiovascular-kidney metabolic disease, and reduced quality of life and life expectancy.

The Obesity Medicine Association (OMA) supports many aspects of the new Dietary Guidelines for Americans , including: A strong emphasis on reducing intake of ultra-processed foods and added sugars A focus on nutrient-dense foods containing fiber, including fruits, vegetables, and whole grains The recommendation to limit saturated fat intake to no more than 10% of total daily calories and to prioritize healthier unsaturated fats Emerging evidence highlighting the importance of nutrition in supporting gut microbiome health Support for extended breastfeeding as beneficial to both maternal and child health At the same time, the OMA emphasizes that obesity is a chronic, relapsing and progressive disease process affecting weight homeostasis.

Learn how non-exercise activity thermogenesis (NEAT) supports obesity treatment and explore clinical guidance to boost patient outcomes.

Childhood obesity rates are climbing worldwide, raising significant public health concerns in an increasingly technology-driven and sedentary world. This trend increases the risk of both short- and long-term health problems, including other serious chronic diseases, mental health challenges, and life-threatening conditions.

It is critical that health care providers can leverage every tool in the obesity care toolbox to develop the best treatment plan for their patients. Sharing this resource – and resources like it - with your patients can help them understand why coverage may have been denied and what steps they can take to access obesity care. Ensure your clinical care team understands approved indications for obesity medicines and can help patients address coverage challenges quickly2 There are many templates and guides available to help your team understand the latest obesity treatment options and tackle common insurance obstacles to help your patients access care. For example: Learn how and why to code for obesity to document treatment effectively and help your patients gain coverage for needed care. By staying informed and raising your voice, and encouraging your patients to do the same, you can help improve coverage for obesity care.

The Trump Administration has announced a proposed plan for a five-year pilot program that will allow patients with Medicare or Medicaid access to anti-obesity medications.